JUN 21, 2018 12:00 PM PDT

Whole Genome Sequencing As A Valuable Clinical Tool For the Management of Cancer Patients

Speaker
  • Professor and Consultant, Department of Laboratory Medicine and Pathology, Mayo Clinic
    Biography
      David I Smith received his Ph.D. in Biochemistry from the University of Wisconsin in Madison in 1978 studying antibiotic resistance in bacteria. After doing post-doctoral work first at the Albert Einstein College of Medicine and then at the University of California, Irvine, he got his first faculty position at Wayne State University in 1985. In 1996 he joined the Mayo Clinic as a full Professor in the Department of Laboratory Medicine and Pathology. His laboratory studies the common fragile sites which are regions of profound genomic instability that are found in all individuals. His laboratory also studies the various ways that human
      papillomavirus is involved in the generation of different cancers. Dr. Smith is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. The role of this group is to evaluate new technologies that could have a profound impact on basic research and its' clinical translation. The most exciting technology that has the greatest potential to change both research and clinical practice is next generation sequencing and Dr. Smith and his group have been using this technology to answer scientific questions. The advances in next generation sequencing over the past 10 years have been nothing
      short of incredible and it is now possible to generate terrabases of DNA sequence in a single run of a next generation sequencer. This technology can be utilized in a number of ways from characterizing just a few genes all the way to whole genome sequencing.

    Abstract

    Advances in DNA sequencing, based upon massively parallel sequencing, has resulted in dramatic advances in DNA sequence output in the past few years. It is now possible to generate terrabases of accurate DNA sequence with a single run on several DNA sequencing platforms. This has then made it possible to characterize alterations that occur during cancer development. Genomic alterations can be characterized by targeted sequencing of genes that are frequently altered during cancer development, by sequencing of the entire exome, transcriptome sequencing, and even by whole genome sequencing. Each of these has their own inherent strengths and weaknesses. I will describe why I believe that the best strategy moving forward for the management of cancer patients is whole genome sequencing (WGS). This can currently be done reliably and inexpensively on two completing platforms. The first is the Illumina sequencing platform and the second is from BGI. WGS is a comprehensive technology that can detect all the alterations in a cancer genome and I will describe how and why this may prove to be the best approach for the management of cancer patients.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    JUN 21, 2018 12:00 PM PDT

    Whole Genome Sequencing As A Valuable Clinical Tool For the Management of Cancer Patients


    Specialty

    Cancer Research

    Immunology

    Gene Expression

    University

    Dna

    Mass Cytometry

    Cancer Diagnostics

    T-Cells

    Bioinformatics

    Immunotherapeutics

    Medicine

    Virology

    Clinical Research

    Gene Sequencing

    Research

    Geography

    North America33%

    Asia33%

    Europe33%

    Registration Source

    Website Visitors100%

    Job Title

    Student67%

    Medical Laboratory Technician33%

    Organization

    Academic Institution33%

    Manufacturer - Other33%

    Other33%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more